Peptide Capture Agents for Botulinum Neurotoxin Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for botulism, including antibodies, face challenges such as rapid sequestration of botulinum neurotoxin (BoNT) into motor neurons, limiting their effectiveness, and the inability of molecular inhibitors to access the occluded active site of circulating BoNT.
Innovation Solution
Development of chemically synthesized capture agents, specifically designed to bind BoNT serotype A, comprising an anchor ligand and a secondary ligand that selectively bind to the toxin, thereby inhibiting its activity and providing a therapeutic and diagnostic solution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to treat botulism, then the toxin can be neutralized, but the rapid sequestration of BoNT into motor neurons limits effectiveness
Solution Approach 1:
The capture agents are designed to bind to BoNT in the extracellular space before the toxin can be sequestered into motor neurons. By performing the neutralizing action in advance, the therapy prevents rather than reacts to the sequestration process, maintaining effectiveness despite rapid neuronal uptake.
Solution Approach 2:
The capture agents act as intermediary molecules that bridge the gap between circulating BoNT and the neuronal targets. These synthetic agents intercept the toxin in the extracellular space, preventing direct neuronal uptake while the antibody-based system works in parallel, thus overcoming the timing limitation.
2Reliability
If molecular inhibitors are used to block the active site, then the toxin activity can be inhibited, but the occluded active site prevents access
Solution Approach 1:
The capture agent is divided into two functional segments: an anchor ligand that binds to the occluded active site and a secondary ligand that binds to an exposed epitope on the light chain. This segmentation allows each component to address a specific binding challenge, with the anchor providing inhibition despite occlusion and the secondary ligand providing stable binding through accessible regions.
Solution Approach 2:
Different regions of the capture agent are designed with different binding characteristics tailored to specific locations on the BoNT structure. The anchor ligand is optimized for interacting with the occluded active site region, while the secondary ligand is optimized for the exposed light chain epitope, allowing the molecule to overcome spatial accessibility issues through localized functional specialization.
3Reliability
If traditional antibodies are used, then the toxin can be detected and neutralized, but stability and specificity are limited
Solution Approach 1:
The capture agent uses a synthetic peptide structure that copies and simplifies the binding function of natural antibodies. Instead of using complex protein antibodies that can be unstable, the invention creates a simplified synthetic molecule that replicates the essential binding and neutralizing functions, improving stability while maintaining detection and neutralization capabilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capture agents effectively inhibit SNAP-25 cleavage mediated by BoNT serotype A, offering a potent treatment for botulism and a means to detect BoNT in biological samples, with enhanced stability and specificity compared to traditional antibodies.
Implementation Method 1
the ligands selectively bind BoNT serotype A
Implementation Method 2
inhibiting SNAP-25 cleavage mediated by botulinum neurotoxin serotype A
Data Source
AI summary
The present application provides stable peptide-based Botulinum neurotoxin (BoNT) serotype A capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing BoNT serotype A capture agents using iterative on-bead in situ click chemistry.